The researchers also found that weight-loss medication use was higher among women than men (4.0% versus 1.7%) and higher among those of middle age (4.2% of 45 and 55-year-olds compared to 1.2% of 18-year-olds and 1.5% of 75-year-olds)
The medication is being prescribed to reduce excess body weight or maintain weight reduction
If your teen doesn't qualify, there's no charge
Limitations: Gastrointestinal adverse effects, particularly nausea and vomiting, were common and contributed to relatively high dropout rates
Obesity Clinical Development Pipeline Muscle and Body Composition Other assets focused on preventing muscle loss in combination with incretin mimetics include Regenerons Phase 2 trevogrumab (myostatin) + garetosmab (ActA) combination, BioAges Phase 2 azelaprag (APJ), and Scholar Rocks Phase 2 apitegromab (myostatin)
GLP-1 medications are increasingly considered long-term metabolic management tools rather than short-term weight loss interventions